Drug-Coated Balloon

SurVeil DCB by Abbott

SurVeil Drug-Coated Balloon (DCB) Overview2

The SurVeil Drug Coated Balloon Catheter (SurVeil DCB) is a drug transfer balloon designed to restore patency to stenotic peripheral arteries (peripheral artery disease (PAD)) through mechanical dilatation and ancillary delivery of a uniform dose of microcrystalline paclitaxel intended to reduce restenosis of the treated peripheral arteries.

The balloon’s excipient polyethyleneimine (PEI) allows for uniform, targeted transfer and retention of microcrystalline paclitaxel to the vessel wall.

The SurVeil DCB is indicated for percutaneous transluminal angioplasty, after appropriate vessel preparation, of de novo or restenotic lesions (≤ 180 mm in length) in femoral and popliteal arteries having reference vessel diameters of 4 mm to 7 mm.

Sustained Drug concentration

SurVeil DCB provided sustained drug tissue concentration through 180 days in pre-clinical testing.1 The balloon excipient polyethyleneimine (PEI) allows for uniform, targeted transfer and retention of microcrystalline paclitaxel to the vessel wall.2

timer icon

Efficient transfer

SurVeil DCB delivered an efficient circumferential transfer of 5X more drug to the target tissue than IN.PACT Admiral in pre-clinical testing.3 SurVeil DCB also demonstrated 60% less drug loss than competitive DCBs in simulated use bench testing.4

plus icon

Excellent clinical outcomes in PAD2

The clinical evidence supporting the safety and effectiveness of SurVeil DCB is from the TRANSCEND study, where SurVeil DCB met its 12-month primary safety endpoint and effectiveness endpoint.2 The SurVeil DCB demonstrated excellent safety and effectiveness at 12, 24 and 36 months. In addition, the lower-dose SurVeil DCB demonstrated comparable freedom from CD-TLR at 36 months compared to the higher-dose IN.PACT Admiral DCB.2,5

timer icon
Request SurVeil DCB Information

To learn more about The SurVeil Drug Coated Balloon Catheter, fill out this form and your local Abbott representative will be in touch shortly.


  1. Results from a 365 days GLP porcine study. Pre-clinical results may not be indicative of clinical performance. Different test methods may yield different results. Data on file at Abbott.
  2. SurVeil Drug-Coated Balloon (DCB) U.S. Instructions for Use (IFU). Refer to IFU for additional information.
  3. Porcine iliofemoral arteries at 28 days post treatment. Pre-clinical results may not be indicative of clinical performance. Different test methods may yield different results. Data on file at Abbott.
  4. Defined as initial device load minus post-content on the balloon and mock vessel. Data on file at Abbott.
  5. Schneider, P. 3-Year Results of a RCT Comparing SurVeil DCBs (Surmodics) with IN.PACT DCBs (Medtronic) for Treating Fempop Lesions: From the TRANSCEND Trial. VEITH 2023.

MAT-2311761 v1.0

Important Safety Information

SurVeil Drug-Coated
Balloon (DCB)



The SurVeil DCB is indicated for percutaneous transluminal angioplasty, after appropriate vessel preparation, of de novo or restenotic lesions (≤ 180 mm in length) in femoral and popliteal arteries having reference vessel diameters of 4 mm to 7 mm.


The SurVeil DCB is contraindicated for use in:

  • Patients who cannot receive recommended antiplatelet and/or anticoagulant therapy
  • Patients with known hypersensitivity to paclitaxel or structurally related compounds
  • Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the delivery system
  • Women who are breastfeeding, pregnant or are intending to become pregnant or men intending to father children
  • Coronary, renal and supra-aortic/cerebrovascular arteries


  • Adhere to the following use parameters for the index procedure:
    • Do not use more balloons than necessary. No more than 200 mm of total balloon length should be used, for a total maximum treatable length of 180 mm.
    • This product should not be used bilaterally or in multiple lesions that cannot be treated with up to 200 mm total balloon length.
    • The safety of exposure to higher doses of the paclitaxel/polyethyleneimine (PEI) drug coating has not been established.
  • The SurVeil DCB is supplied STERILE for SINGLE USE ONLY. Do not reuse and/or resterilize.
  • Do not open sterile package until you are ready to begin the procedure.
  • Do not use if the integrity of the sterile package has been compromised or if any sterile package or product defects are noted.
  • Do not use after the Use by Date on the label.
  • Do not exceed the rated burst pressure (RBP) recommended in the compliance chart for this device specified on device packaging.
  • To minimize the potential for vessel damage, ensure the expected inflated diameter of the balloon approximates the intended treatment segment.
  • Do not use any gaseous medium to inflate the balloon.
  • Do not use device if air does not aspirate properly.
  • Completely deflate the balloon and maintain negative pressure before withdrawing it from the dilated area.
  • The safety and effectiveness of utilizing multiple SurVeil DCBs with a total drug dosage exceeding 9048 μg of paclitaxel in a patient has not been clinically evaluated in the TRANSCEND trial.

DO NOT REUSE and/or RESTERILIZE the SurVeil DCB. Reuse and/or resterilization may create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s). Contamination of the device may lead to injury, illness, or death of the patient. Reuse and/or resterilization may compromise integrity of the device, including the drug coating, or lead to device failure, which may result in patient injury, illness, or death. Surmodics is not responsible for any direct, incidental, or consequential damages resulting from reuse and/or resterilization.


  • The SurVeil DCB is only to be used by clinicians trained in peripheral vascular percutaneous interventional procedures. A thorough understanding of the technical principles, clinical applications and risks associated with percutaneous transluminal angioplasty is necessary before using the SurVeil DCB.
  • Consideration should be given to the risks and benefits of use in patients with a history of non-controllable allergies to contrast solution.
  • Use only the recommended balloon inflation solution (50% contrast / 50% sterile saline).
  • Administer appropriate drug therapy to the patient according to standard protocols for PTA before insertion of the dilatation catheter.
  • Take precautions to prevent or reduce clotting when any catheter is used. Flush and rinse all products entering the vascular system with heparinized normal saline or a similar solution. For the SurVeil DCB, flush the guidewire lumen through the guidewire port with heparinized normal saline until the fluid exits the distal tip. Do not rinse or wipe the SurVeil DCB.
  • Keep the SurVeil DCB dry prior to insertion into the body. Replace any device that has come into contact with fluids prior to use.
    • Do not immerse the SurVeil DCB in a saline bath.
    • Handle the SurVeil DCB only with dry sterile gloves.
    • Avoid moisture contact with the balloon.
  • Minimize contact with the coated balloon. Extended manipulation of the SurVeil DCB can cause loss of coating integrity.
  • Keep the balloon sheath in place during preparation of the SurVeil DCB. Remove the balloon sheath immediately before placing over guidewire.
  • If difficulty is encountered while removing the balloon sheath, discard device and use a new SurVeil DCB.
  • Do not attempt to pass the SurVeil DCB through an introducer that is smaller than indicated in the list of required materials or on the primary package label.
  • Do not inflate the balloon outside the body or prior to reaching the target segment as it may disrupt the drug coating.
  • Always advance and withdraw the SurVeil DCB under negative pressure.
  • Do not use the SurVeil DCB if the shaft has been bent or kinked because device function could be compromised.
  • Do not advance the SurVeil DCB if resistance is met.
  • Do not move the guidewire or reposition once inflation has begun.
  • Only change the position of the balloon catheter with the guidewire in place.
  • Do not over-tighten the hemostatic valve around the SurVeil DCB as lumen constriction may occur, affecting inflation/deflation of the balloon. Advance the SurVeil DCB to the target segment in an efficient manner and immediately inflate.
  • To prevent over-pressurization, use a pressure monitoring device.
  • Minimize the number of contrast solution injections during positioning to ensure appropriate drug delivery to lesion.
  • Use of the SurVeil DCB in conjunction with other drug-eluting stents or drug-coated balloons in the same procedure or following treatment failure has not been evaluated.

Pre- and post-procedure medication regimen
It is strongly advised that the treating physician follow the Inter- Society Consensus (TASC II) Guidelines recommendations (or other applicable country guidelines) for antiplatelet therapy pre- and post-procedure

Potential Adverse Events

Potential adverse events, which may be associated with the use of a peripheral-dilatation balloon catheter procedure may include, but are not limited to, the following:

  • Acute re-occlusion necessitating surgical intervention
  • Allergic reaction to contrast solution, anti-platelet therapy, or catheter system components
  • Amputation
  • Aneurysm
  • Arrhythmias
  • Arterio-venous fistula
  • Bleeding
  • Death
  • Endocarditis
  • Femoral nerve compression with associated neuropathy
  • Groin area bruising and discomfort
  • Ischemia or infarction of tissue/organ
  • Renal insufficiency or failure
  • Local hematoma
  • Local hemorrhage
  • Local infections
  • Local or distal thromboembolic episodes
  • Low blood pressure
  • Pain and tenderness
  • Pseudoaneurysm
  • Pyrogenic reaction
  • Respiratory failure
  • Restenosis of the dilated artery
  • Sepsis/infection
  • Short-term hemodynamic deterioration
  • Stroke
  • Systemic embolization
  • Total occlusion or thrombosis
  • Vessel damage, dissection, perforation, rupture, or spasm

Potential adverse events that may be unique to the paclitaxel drug coating may include, but are not limited to:

  • Allergic/immunologic reaction
  • Alopecia
  • Anemia
  • Gastrointestinal symptoms
  • Hematologic dyscrasia (including leukopenia, neutropenia, thrombocytopenia)
  • Hepatic enzyme changes
  • Histologic changes in vessel wall, including inflammation, cellular damage, or necrosis
  • Myalgia/arthralgia
  • Myelosuppression
  • Peripheral neuropathy

SurVeil is manufactured by Surmodics, Inc., distributed by Abbott Group of Companies

MAT-2213996 v1.0